Low-Carbohydrate and Ketogenic Dietary Patterns for Type 2 Diabetes Management

Robert C Oh
{"title":"Low-Carbohydrate and Ketogenic Dietary Patterns for Type 2 Diabetes Management","authors":"Robert C Oh","doi":"10.12788/fp.0429","DOIUrl":null,"url":null,"abstract":"Background: Type 2 diabetes mellitus (T2DM) has been traditionally considered a chronic, progressive disease. Since 2017, guidelines from the US Department of Veterans Affairs and US Department of Defense have included low-carbohydrate (LC) dietary patterns in managing T2DM. Recently, carbohydrate reduction, including ketogenic diets, has gained renewed interest in the management and remission of T2DM. Observations: This narrative review examines the evidence behind carbohydrate reduction in T2DM and a practical guide for clinicians starting patients on therapeutic LC diets. We present an illustrative case and provide practical approaches to prescribing a very LC ketogenic (< 50 g), LC (50-100 g), or a moderate LC (101-150 g) dietary plan and discuss adverse effects and management of LC diets. We provide a medication management and deprescription approach and discuss strategies to consider in conjunction with LC diets. As patients adopt LC diets, glycemia improves, and medications are deprescribed, hemoglobin A 1c levels and fasting glucose may drop below the diagnostic threshold for T2DM. Remission of T2DM may occur with LC diets (hemoglobin A 1c < 6.5% for ≥ 3 months without T2DM medications). Finally, we describe barriers and limitations to applying therapeutic carbohydrate reduction in a federal health care system. Conclusions: The effective use of LC diets with close and intensive lifestyle counseling and a safe approach to medication management and deprescribing can improve glycemic control, reduce the overall need for insulin and medication and provide sustained weight loss. The efficacy and continuation of therapeutic carbohydrate reduction for patients with T2DM appears promising. Further research on LC diets, emerging strategies, and long-term effects on cardiometabolic risk factors, morbidity, and mortality will continue to inform practice.","PeriodicalId":513268,"journal":{"name":"Federal Practitioner","volume":"52 7","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Federal Practitioner","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12788/fp.0429","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Type 2 diabetes mellitus (T2DM) has been traditionally considered a chronic, progressive disease. Since 2017, guidelines from the US Department of Veterans Affairs and US Department of Defense have included low-carbohydrate (LC) dietary patterns in managing T2DM. Recently, carbohydrate reduction, including ketogenic diets, has gained renewed interest in the management and remission of T2DM. Observations: This narrative review examines the evidence behind carbohydrate reduction in T2DM and a practical guide for clinicians starting patients on therapeutic LC diets. We present an illustrative case and provide practical approaches to prescribing a very LC ketogenic (< 50 g), LC (50-100 g), or a moderate LC (101-150 g) dietary plan and discuss adverse effects and management of LC diets. We provide a medication management and deprescription approach and discuss strategies to consider in conjunction with LC diets. As patients adopt LC diets, glycemia improves, and medications are deprescribed, hemoglobin A 1c levels and fasting glucose may drop below the diagnostic threshold for T2DM. Remission of T2DM may occur with LC diets (hemoglobin A 1c < 6.5% for ≥ 3 months without T2DM medications). Finally, we describe barriers and limitations to applying therapeutic carbohydrate reduction in a federal health care system. Conclusions: The effective use of LC diets with close and intensive lifestyle counseling and a safe approach to medication management and deprescribing can improve glycemic control, reduce the overall need for insulin and medication and provide sustained weight loss. The efficacy and continuation of therapeutic carbohydrate reduction for patients with T2DM appears promising. Further research on LC diets, emerging strategies, and long-term effects on cardiometabolic risk factors, morbidity, and mortality will continue to inform practice.
治疗 2 型糖尿病的低碳水化合物和生酮饮食模式
背景:2 型糖尿病(T2DM)历来被认为是一种慢性、进展性疾病。自 2017 年以来,美国退伍军人事务部和美国国防部的指南已将低碳水化合物(LC)饮食模式纳入 T2DM 的管理中。最近,减少碳水化合物(包括生酮饮食)在 T2DM 的管理和缓解方面再次受到关注。评论:这篇叙述性综述探讨了减少 T2DM 中碳水化合物的证据,并为临床医生指导患者开始治疗性低碳水化合物饮食提供了实用指南。我们介绍了一个说明性病例,并提供了开具极低碳水化合物生酮(< 50 克)、低碳水化合物(50-100 克)或中度低碳水化合物(101-150 克)饮食计划的实用方法,还讨论了低碳水化合物饮食的不良反应和管理。我们提供了药物管理和停药方法,并讨论了配合低脂饮食的策略。随着患者采用低脂饮食,血糖改善,药物停用,血红蛋白 A 1c 水平和空腹血糖可能降至 T2DM 诊断阈值以下。采用低脂饮食可缓解 T2DM(血红蛋白 A 1c < 6.5%,持续时间≥ 3 个月,且无需服用 T2DM 药物)。最后,我们介绍了在联邦医疗保健系统中应用治疗性碳水化合物减量的障碍和限制。结论:有效使用低碳水化合物饮食,配合密切和深入的生活方式咨询,以及安全的药物管理和停药方法,可以改善血糖控制,减少对胰岛素和药物的总体需求,并提供持续的体重减轻。对 T2DM 患者进行治疗性碳水化合物减量的疗效和持续性似乎很有希望。有关低碳水化合物饮食、新兴策略以及对心脏代谢风险因素、发病率和死亡率的长期影响的进一步研究将继续为实践提供参考。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信